stockrowArcus Biosciences, Inc.
RCUS Healthcare Biotechnology
Arcus Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $247.0 million, down 4.26% from fiscal 2024.
- Revenue
- −65.4%
- EPS
- +21.3%
- Free cash flow
- +9.28%
- Total debt
- +4.08%
Quarter to September 2026, against a year earlier
Follow RCUS
Alert me
Arcus Biosciences, Inc. (RCUS) Revenue
Arcus Biosciences, Inc.'s revenue for fiscal 2025 was $247.0M, unchanged from fiscal 2024. Over the twelve months to 30 September 2026 it was $100.0M. Over the past ten years it has ranged from $1.4M (fiscal 2017) to $383.0M (fiscal 2021); the current reading is higher than 78% of that period. Arcus Biosciences, Inc. ranks 96th of 390 Biotechnology companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $247.0M | (4.26%) |
| FY2024 | $258.0M | 120.51% |
| FY2023 | $117.0M | 4.46% |
| FY2022 | $112.0M | (70.76%) |
| FY2021 | $383.0M | 391.03% |
| FY2020 | $78.0M | 420.00% |
| FY2019 | $15.0M | 79.58% |
| FY2018 | $8.4M | 491.15% |
| FY2017 | $1.4M | — |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $9.0M | (78.05%) |
| Jun 2026 | $41.0M | 141.18% |
| Mar 2026 | $17.0M | (48.48%) |
| Dec 2025 | $33.0M | 26.92% |
| 33 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| ZLAB Zai Lab Limited Unsponsored ADR compare | $441.7M |
| BEAM Beam Therapeutics Inc. compare | $146.6M |
| XNCR Xencor, Inc. compare | $105.0M |
| RCUS Arcus Biosciences, Inc. | $100.0M |
| RXRX Recursion Pharmaceuticals, Inc. compare | $68.2M |
| IDYA IDEAYA Biosciences, Inc. compare | $36.5M |
| NAMS NewAmsterdam Pharma Company N.V. compare | $25.9M |
| PHVS Pharvaris N.V. compare | — |
| MBX MBX Biosciences, Inc. compare | — |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on RCUS
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement